University of Limerick Institutional Repository

SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study

DSpace Repository

Show simple item record O'Callaghan, Michael Ryan, Elizabeth J. Walsh, Cathal Dominic Hayes, Peter Casey, Monica O'Dwyer, Pat Culhane, Aidan Duncan, John W. Harrold, Pat Healy, Jarlath Kerin, Emmet Kelly, Eimear Hanrahan, Conor Lane, Ger P. Lynch, Bernie Meaney, Paraic O'Connell, Billy Galvin, Jim Kennedy, Norelee Burke, Paul O'Connell, Nuala H. Dunne, Colum P. Glynn, Liam G. 2021-07-08T13:37:29Z 2021-07-08T13:37:29Z 2021
dc.description peer-reviewed en_US
dc.description.abstract Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody testing in community settings may help us better understand the immune response to this virus and, therefore, help guide public health efforts. Aim: To conduct a seroprevalence study of immunoglobulin G (IgG) antibodies in Irish GP clinics. Design & setting: Participants were 172 staff and 799 patients from 15 general practices in the Midwest region of Ireland. Method: This seroprevalence study utilised two manufacturers’ point-of-care (POC) SARS-CoV-2 immunoglobulin M (IgM)—IgG combined antibody tests, which were offered to patients and staff in general practice from 15 June to 10 July 2020. Results: IgG seroprevalence was 12.6% in patients attending general practice and 11.1% in staff working in general practice, with administrative staff having the lowest seroprevalence at 2.5% and nursing staff having the highest at 17.6%. Previous symptoms suggestive of COVID-19 and history of a polymerase chain reaction (PCR) test were associated with higher seroprevalence. IgG antibodies were detected in approximately 80% of participants who had a previous PCR-confirmed infection. Average length of time between participants’ positive PCR test and positive IgG antibody test was 83 days. Conclusion: Patients and healthcare staff in general practice in Ireland had relatively high rates of IgG to SARS-CoV-2 compared with the national average between 15 June and 10 July 2020 (1.7%). Four fifths of participants with a history of confirmed COVID-19 disease still had detectable antibodies an average of 12 weeks post-infection. While not proof of immunity, SARS-CoV-2 POC testing can be used to estimate IgG seroprevalence in general practice settings. en_US
dc.language.iso eng en_US
dc.publisher Royal College of General Practitioners en_US
dc.relation.ispartofseries BJGP;
dc.subject coronavirus en_US
dc.subject acute respiratory syndrome en_US
dc.title SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.3399/BJGPO.2021.0038
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


My Account